A Cedars-Sinai study in JAMA Network Open reports women testing negative for BRCA mutations but with a family cancer history face a 25% lifetime breast cancer risk, underscoring the importance of family history in risk assessment.
The FDA has granted Breakthrough Device designation to PreludeDx’s AidaBREAST assay, which uses multi-omic data and AI to assess recurrence risk and radiation therapy benefit in early-stage invasive breast cancer.
Researchers found that circulating tumor DNA testing could identify which older patients with estrogen receptor–positive breast cancer are less likely to respond to hormone therapy alone.
A blinded validation in more than 400 women shows the test provides clearer guidance on recurrence risk and radiation therapy decisions.
Read More
Coverage applies to stage II and III breast cancer patients across three major subtypes for up to six years of recurrence monitoring.
Read More
The research‑use‑only test for post‑treatment breast cancer monitoring is now available through the company’s affiliate EG Biomed US.
Read More
The agreement focuses on clinical validation of ESR1 mutation detection assay for advanced breast cancer testing using ddPCR technology.
Read More
Researchers develop PIPscore using plasma proteomics to identify triple-negative breast cancer patients most likely to benefit from immunotherapy treatment.
Read More
Coverage marks a step in expanding access to ultra-sensitive molecular residual disease detection for breast cancer patients.
Read More
Emerging liquid biopsy techniques enable sensitive, routine monitoring of ESR1 mutations in metastatic HR+ breast cancer.
Read More
Personalis, Inc. unveiled promising new clinical data from the PREDICT DNA and SCANDARE studies at ASCO 2025.
Read More
SAGA Diagnostics has launched Pathlight, a groundbreaking multi-cancer blood test for ultra-sensitive detection of MRD.
Read More
Hologic and Biotheranostics unveiled new data showing that the Breast Cancer Index (BCI) test improves treatment decision-making.
Read More
A groundbreaking genetic study identified two novel breast cancer-linked genetic variants in Black South African women.
Read More
A new peer-reviewed study confirms that Ibex Breast significantly enhances accuracy, speed, and efficiency of breast pathology evaluations.
Read More
A new editorial discusses findings from the COMET trial, suggesting that early-stage breast cancer may not require immediate surgery.
Read More
Roche’s PATHWAY anti-HER2/neu (4B5) test has received FDA approval to ID patients with HR-positive, HER2-ultralow metastatic breast cancer.
Read More
BioView’s liquid biopsy test offers a non-invasive method to detect HER2 status in metastatic breast cancer patients.
Read More